Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Oramed Pharmaceuticals (ORMP) Long-Term Debt Repayments (2023 - 2025)

Oramed Pharmaceuticals filings provide 3 years of Long-Term Debt Repayments readings, the most recent being $65.5 million for Q2 2025.

Quarterly Long-Term Debt Repayments rose 114.33% to $65.5 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $134.7 million through Dec 2025, up 171.8% year-over-year, with the annual reading at $69.2 million for FY2025, 39.66% up from the prior year.
Long-Term Debt Repayments hit $65.5 million in Q2 2025 for Oramed Pharmaceuticals, down from $69.2 million in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $69.2 million in Q1 2025 and bottomed at $19.0 million in Q1 2024.
Average Long-Term Debt Repayments over 3 years is $41.8 million, with a median of $30.6 million recorded in 2024.
Peak annual rise in Long-Term Debt Repayments hit 264.21% in 2025, while the deepest fall reached 114.33% in 2025.
Oramed Pharmaceuticals' Long-Term Debt Repayments stood at $25.0 million in 2023, then increased by 22.2% to $30.6 million in 2024, then soared by 114.33% to $65.5 million in 2025.
Per Business Quant, the three most recent readings for ORMP's Long-Term Debt Repayments are $65.5 million (Q2 2025), $69.2 million (Q1 2025), and $30.6 million (Q2 2024).